Company intelligence

LXEO

Lexeo Therapeutics, Inc. Common Stock · NASDAQ · Healthcare

Price$4.08-2.86% · −$0.12

Market cap320.37MEquity value

P / E-3.5Trailing ratio

Volume854.78KLatest session

Market data

LXEO price chart

TradingView

Related signals

1 min delayed

Browse public LXEO signals with their source context and measured market impact. Open any signal for its permanent analysis page.

LXEOJun 15, 2026-3.06% since signal

Lexeo Advances SUNRISE-FA 2 Trial with Key 2027–2028 Milestones

Lexeo finalized the SUNRISE-FA 2 protocol for LX2006 in Friedreich ataxia cardiomyopathy, with enrollment by June 2026 and first dosing imminent. Topline data are targeted for H2 2027, followed by an FDA accelerated-approval submission in H1 2028. Positive progress may unlock near-term upside, but valuation hinges on ongoing execution and financing.

View signal analysis

LXEOApr 7, 2025-5.45% since signal

Gene Therapy For Fatal Rare Disease-Associated Heart Condition - Lexeo Therapeutics Candidate Shows Improvements In Trials

Interim data for LX2006 shows significant cardiac improvements in Friedreich ataxia patients. 5 of 6 participants achieved normal LVMI, indicating strong treatment efficacy. 27% mean LVMI improvement reflects dose-dependent efficacy across treatment cohorts. All participants noted increased frataxin protein expression in cardiac biopsies. Lexeo plans a registrational study by early 2026, aiming for a 2027 readout.

View signal analysis

Research